Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky Lexington, Lexington, KY 40536; and.
J Lipid Res. 2013 Oct;54(10):2775-84. doi: 10.1194/jlr.M039685. Epub 2013 Aug 15.
Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase-resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ∼90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans.
溶血磷脂酸 (LPA) 是一种生物活性脂质介质。在给予一种有效的选择性溶血磷脂酶 D 自分泌酶(即 LPA 生成酶)抑制剂后,小鼠血浆中主要 LPA 种类的浓度均匀下降,这确定了一种从循环中去除 LPA 的主动机制。LPA、酰基甘油磷酸 (AGP)、鞘氨醇 1-磷酸 (S1P) 以及这些脂质的各种结构类似物,包括 LPA 的磷酸酶抗性膦酸酯类似物,在静脉内给予单次推注剂量后,从小鼠循环中迅速消除(t1/2 < 30s),而在血液中没有明显的原位代谢。这些脂质在肝脏中积累。结扎肝循环会使静脉内给予的 LPA 消除减弱,通过门静脉给予的约 90%的 LPA 在首次通过时被分离的灌注鼠肝积累。在静脉内给予后的早期,与肝细胞相比,更多的 LPA 与非实质细胞肝脏细胞部分相关。非实质细胞肝脏细胞的原代培养物迅速同化外源性提供的 LPA。我们的结果确定了肝摄取是 LPA 和生物活性溶血磷脂类似物生物利用度的重要决定因素,并提出了一种机制来解释与人类肝功能障碍相关的循环 LPA 水平变化。